Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 19 от 154

Набира участници Фаза 3

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

High Risk Cardiovascular Disease Hypertension High Cardiovascular Risk

The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.

Начало: 22.09.2025 Край: 30.09.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +23 Alnylam Pharmaceuticals NCT07181109

Набира участници Фаза 1/2

A Study of YL242 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.

Начало: 22.09.2025 Край: 01.11.2028 Възраст: от 18 г. Лечение

Australia, China, United States MediLink Therapeutics (Suzhou) Co., Ltd. NCT07197827

Набира участници

Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension

Hypertension Vascular Diseases Cardiovascular Diseases Chronic Kidney Diseases +1

The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.

Начало: 22.09.2025 Край: 31.12.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Germany +5 Medtronic Vascular NCT07115953

Набира участници

Study of Student Flourishing

Healthy

The goal of this study is to learn how a science-based mobile app, called Flourish, affects student well-being. The main questions it aims to answer are: 1. Does receiving access to the Flourish app increase well-being (e.g., positive affect, loneliness, belonging) among students? 2. Does using the Flourish app in combination with a human buddy/friend lead to better outcomes than using the app alone? Researchers will compare three different groups to see if and how the Flourish app works to improve student well-being: 1. Waitlist Control Group: Students continue with existing school resources. 2. Flourish App Group: Students use the Flourish app (a digital toolkit and AI chatbot) twice per week. 3. Flourish App + Buddy Group: Students use the Flourish app twice per week with someone else as a "Flourish Buddy". Participants will: Be randomly assigned to one of the three groups listed above. Use the app or continue with regular resources for 6 weeks. Complete four short online surveys about their well-being (at the beginning, during the 6 weeks, and at the end).

Начало: 22.09.2025 Край: 01.05.2026 Възраст: от 18 г. Превенция

Canada, New Zealand, United States Flourish Science, Inc. NCT07259746

Набира участници

STarting incrEmental Prescription of Peritoneal Dialysis

Peritoneal Dialysis (PD) Kidney Failure

Kidney failure is fatal without dialysis. Peritoneal dialysis (PD) completed at home offers greater flexibility and autonomy for patients . However, PD is often prescribed for 24 hours/day, 7 days/week for every patient starting dialysis. This practice is not evidence-informed, may be unnecessary and potentially harmful. The STEP-PD trial aims to determine the optimal approach to commencing patients on PD through starting at low dose PD and incrementing over time.

Начало: 19.09.2025 Край: 30.09.2029 Възраст: от 18 г. Лечение

Australia, South Korea, Taiwan +1 The University of Queensland NCT06642597

Набира участници Фаза 4

Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment

Retinal Detachment

Retinal detachment occurs when fluid separates the retina (a thin, light sensing tissue) from its usual attachment at the back of the eye. If detached, these retinal cells lose their normal blood supply and begin to die, which is the primary cause of vision loss in retinal detachment. The 'macula' refers to the very centre of the retina, with the highest density of retinal cells, most responsible for vision. Significant vision loss occurs when this part of the retina becomes separated (termed a 'macula-off retinal detachment'). Typically, surgery is required to repair the retinal detachment. Supporting the health of retinal cells at the macula may prolong their survival after detachment and their recovery postoperatively. Recent evidence has shown that boosting our nicotinamide adenine dinucleotide (NAD+) levels may improve the health of these cells and prolong their survival if detached. Oral Nicotinamide Riboside (NR) is converted into NAD+, and while not studied for macula-off retinal detachments, has been safely used in a range of other conditions. This study is designed to help evaluate the safety and tolerability of NR to help preserve vision in people diagnosed with macula-off retinal detachment. This study drug is given as an oral supplement (tablet) at the time of retinal detachment diagnosis, and daily for 20 weeks thereafter. The drug aims to prolong survival of cells in the retina (and macula) and their recovery after surgery. The long-term goal of this treatment is to reduce loss of vision after retinal detachment. The researchers will compare NR to a placebo (a look-alike substance that contains no drug) to see if NR has a positive effect on photoreceptor survival and quality of vision postoperatively. NR has been approved by the Therapeutic Goods Administration in Australia for many purposes but has not been approved for use in retinal detachment treatment.

Начало: 19.09.2025 Край: 30.03.2028 Възраст: от 18 г. Лечение

Australia Center for Eye Research Australia NCT06587945

Набира участници Фаза 2

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

Ocular Graft Versus Host Disease

An 84-day, prospective, randomized (1:1) vehicle controlled, double-masked pre-market, crossover study. Subjects with moderate to severe oGVHD related Dry Eye Disease Each subject will receive both treatments in random sequence, each for 28 days, separated by a 14-day vehicle washout period.

Начало: 17.09.2025 Край: 01.12.2026 Възраст: 18–75 г. Лечение

Australia Lubris Bio Pty Ltd NCT07118254

Набира участници Фаза 2

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

Sjögren's Syndrome

rhPRG4-Sjögren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjögren's related Dry Eye Disease.

Начало: 17.09.2025 Край: 01.08.2026 Възраст: 18–75 г. Лечение

Australia Lubris Bio Pty Ltd NCT07118241

Набира участници

Perspectives on Antibiotics and Tracking Symptoms in Children

Urinary Tract Infection Cellulitis Impetigo Pharyngitis +3

The study will assess families' perspectives and decision-making regarding the duration of oral antibiotic courses prescribed to children (4-17 years) who present with uncomplicated bacterial infections at the Royal Children's Hospital (RCH) Emergency Department (ED). The study will involve (i) children discharged from ED on oral antibiotics and (ii) children transferred to Hospital-in-the-Home (HITH) on IV antibiotics who then switch to oral antibiotics. In addition, the study will assess how feasible and acceptable it is to track children's symptoms via the Garmin Smartwatch and the WeGuide platform (WeGuide is a patient engagement software platform that allows for enrolment, consent, and data collection \[via questionnaires/surveys and from the Garmin Smartwatches\] through a singular platform).

Начало: 16.09.2025 Край: 01.08.2026 Възраст: 4–17 г. Друго

Australia Murdoch Childrens Research Institute NCT07093749

Набира участници Фаза 2

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

COVID - 19

This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.

Начало: 16.09.2025 Край: 01.03.2026 Възраст: от 18 г. Лечение

Australia, South Korea, Taiwan +1 Traws Pharma, Inc. NCT07157007

Набира участници

IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma

Melanoma (Skin Cancer)

This study aims to capture information regarding the effect of immune checkpoint inhibitor (ICI) treatment for melanoma on reproductive organ function and sex hormone levels. You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with melanoma (Stage II, III or IV) and you are planning to receive ICI treatment. Additional criteria will apply dependent upon your biological sex characteristics. All participants who choose to enroll in this study will be asked to complete a series of questionnaires and provide blood at 4 of their scheduled treatment visits. These visits are anticipated to add 30 minutes to the scheduled visit time. Male participants will also be asked to provide semen samples at 2 of their scheduled treatment visits. These visits are anticipated to add an additional 30 minutes to the scheduled visit time. No additional or novel treatments will be offered to participants who choose to enroll in this study, this is an observational study only. It is hoped this research will contribute important information regarding the potential toxic effects of ICI treatment on sexual and reproductive function in patients with melanoma who are receiving ICI treatment.

Начало: 11.09.2025 Край: 01.12.2027 Възраст: 18–60 г.

Australia Peter MacCallum Cancer Centre, Australia NCT07138222

Набира участници Фаза 2/3

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Breast Neoplasms

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies.

Начало: 11.09.2025 Край: 15.05.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +22 Bristol-Myers Squibb NCT06926868

Набира участници

Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

Aortic Stenosis Treated With TAVI Aortic Diseases

The objective of this study is to compare the safety and effectiveness of the F2 Cerebral Protection System (CPS) to a standard of care control group in patients undergoing Transcatheter Aortic Valve Replacement (TF TAVR)

Начало: 09.09.2025 Край: 01.01.2027 Възраст: от 50 г. Лечение

Australia, United States EnCompass Technologies, Inc. NCT06689839

Набира участници Фаза 1

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Refractory Autoimmune Diseases

The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.

Начало: 04.09.2025 Край: 16.08.2030 Възраст: от 18 г. Лечение

Australia, Brazil, Czechia +7 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company NCT07115745

Набира участници Фаза 2

Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

Non-cystic Fibrosis Bronchiectasis

This study is a phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose range finding study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (immunoglobulin G \[IgG\] inhalation solution) compared with placebo over a period of 6 to 12 months independent of the occurrence of pulmonary exacerbations. The primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 active treatment regimens of inhaled CSL787 administered to participants with NCFB toward prolonging the TTF exacerbation.

Начало: 03.09.2025 Край: 28.03.2028 Възраст: 18–85 г. Лечение

Australia, Japan CSL Behring NCT07048262

Набира участници

Treatable Traits in Interstitial Lung Disease

Interstitial Lung Diseases (ILD)

The goal of this clinical trial is to learn if a personalised treatment model of care "treatable traits" can improve quality of life and disease progression in patients with interstitial lung disease. The main question it aims to answer is, will providing a treatable traits model of care improve health-related quality of life (HRQoL) (primary outcome), symptoms, anxiety, physical activity, and body composition (secondary outcomes). Researchers will compare the treatable traits model to standard of care. Participants in both arms will complete surveys, a Dual-Energy X-Ray Absorptiometry (DEXA) and whole-body composition scan, lung function and blood tests. Those in the intervention (TT) arm will be seen in a multidisciplinary clinic where they are seen by an ILD doctor, physiotherapist, psychologist, and dietitian.

Начало: 03.09.2025 Край: 01.07.2027 Възраст: от 18 г. Лечение

Australia The University of Western Australia NCT06626438

Набира участници Фаза 1

Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants

Healthy Participants

This is a first-in-human, randomized, double-blind, placebo-controlled Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered LTG-321 in healthy male and female participants 18 to 55 years of age. The study will be conducted in New Zealand. The study also includes a randomized, double-blind, placebo-controlled, within-participant crossover evaluation of pain tolerance using a cold pressor test in healthy male participants 18 to 55 years of age. In addition, a randomized, open-label, crossover Food Effect cohort will evaluate the impact of a high-fat meal on the pharmacokinetics of LTG-321 following single oral doses in the fed and fasted state.

Начало: 03.09.2025 Край: 01.07.2026 Възраст: 18–55 г. Лечение

New Zealand Latigo Biotherapeutics NCT07110610

Набира участници Фаза 3

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Neoplasms

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).

Начало: 02.09.2025 Край: 30.05.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +14 Janssen Research & Development, LLC NCT07164443

Набира участници

The Reboot Study: A Safety Study of Abdominal Vagus Nerve Stimulation for Moderate to Severe Drug Refractory Rheumatoid Arthritis

Arthritis, Rheumatoid

This open label clinical trial aims to assess the safety of abdominal vagus nerve stimulation (aVNS) for moderate to severe, adult-onset rheumatoid arthritis (RA) that has not responded to medication. The aVNS is an active medical device placed into the body to allow electrical stimulation of the abdominal vagus nerve. Participants will undergo stimulation treatment with the aVNS device from two to 24 weeks after the device is implanted by keyhole surgery. Safety, device performance and potential benefits will be assessed. Participants will be monitored for specific events for 5 years post surgery.

Начало: 01.09.2025 Край: 01.12.2031 Възраст: 18–75 г. Устройства

Australia The Bionics Institute of Australia NCT07017686

Набира участници Фаза 2

A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa

Retinitis Pigmentosa

The goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injection bilaterally every 6 weeks in patients with late-stage retinitis pigmentosa (RP). Late-stage RP patients will include those patients with No Light Perception (NLP), or Low Vision (LV).

Начало: 29.08.2025 Край: 01.08.2027 Възраст: от 18 г. Лечение

Australia Kiora Pharmaceuticals, Inc. NCT06628947

1 … 17 18 19 20 21 … 154